Zheru Zhang and Jielun Zhu of I-Mab Biopharma, shares their vision for the ambitious biotech company looking to develop their dual-pronged strategy of in-licensing ‘fast-to-market’ assets for their China portfolio while accelerating proof-of-concept of their internally developed candidates; what it means to operate at ‘I-Mab speed’, not just ‘China Speed’; the importance of their US presence; and their dream of developing I-Mab into an integrated end-to-end global biopharma company.
Speed is of critical importance, particularly in the competitive field of immuno-oncology
